Determination of the Clinical Growth Index in Unilateral Vestibular Schwannoma

ABSTRACT

Objectives: To analyze factors associated with the clinical growth index of sporadic unilateral vestibular schwannoma and to evaluate the validity of the index as an indicator of tumor growth. Design: A retrospective case review study. Patients and methods: A series of 118 patients with unilateral vestibular schwannomas. Clinical growth index was calculated by dividing tumor size by the length of clinical history. Clinical growth index, tumor size, symptoms, and symptom duration were tested for a relationship with tumor location, patient sex, and age. All tests were performed for the total group and separately for three subgroups: intrameatal tumors (IT group, n = 46), intrameatal and extrameatal tumors (IET group, n = 60), and extrameatal tumors (ET group, n = 12). Results: Vestibular schwannoma diameter ranged from 3 to 40 mm (mean size, 14.3 ± 7.6 mm). The maximum tumor diameter was significantly greater for the IET group (17.9 ± 6.5 mm) and the ET group (19.3 ± 8.5 mm) than for the IT group (8.5 ± 4.3 mm) (p < 0.001). The mean clinical growth index was determined as being 31.3 ± 55.7 mm/yr for the total group. A significantly lower clinical growth index was found for the IT group (14.7 ± 25.3 mm/yr) compared with the IET group (41.9 ± 69.2 mm/yr) and the ET group (43.3 ± 52.4 mm/yr) (p = 0.031). A significantly negative correlation between the clinical growth index and the age of the patients was noted for both the total group (p = 0.010) and the IET group (p = 0.017). A significantly negative correlation between the tumor size and the age of the patients was determined for the ET group (p = 0.22). Conclusions: This study demonstrates a lower clinical growth index and smaller tumors in the older population, supporting data previously presented by extensive radiological studies. Our findings might provide a rationale for the consideration of the clinical growth index to estimate vestibular schwannoma growth rate.

KEYWORDS

Vestibular schwannoma - clinical growth index - growth rate - age

REFERENCES

• 1 Tos M, Stangerup S E, Caye-Thomasen P, Tos T, Thomsen J. What is the real incidence of vestibular schwannoma?.  Arch Otolaryngol Head Neck Surg. 2004;  130 216-220
• 2 Tos M, Charabi S, Thomsen J. Incidence of vestibular schwannomas.  Laryngoscope. 1999;  109 736-740
• 3 Neary W J, Newton V E, Laoide-Kemp S N et al.. A clinical, genetic and audiological study of patients and families with unilateral vestibular schwannomas. I. Clinical features of neurofibromatosis in patients with unilateral vestibular schwannomas.  J Laryngol Otol. 1996;  110 634-640
• 4 House W F. Transtemporal bone microsurgical removal of acoustic neuromas.  Arch Otolaryngol. 1964;  80 599-676
• 5 Samii M, Matthies C. Gamma surgery for vestibular schwannoma.  J Neurosurg. 2000;  92 892-894
• 6 Tschudi D C, Linder T E, Fisch U. Conservative management of unilateral acoustic neuromas.  Am J Otol. 2000;  21 722-728
• 7 Cardillo M R, Filipo R, Monini S, Aliotta N, Barbara M. Transforming growth factor-beta1 expression in human acoustic neuroma.  Am J Otol. 1999;  20 65-68
• 8 Wazen J, Silverstein H, Norrell H, Besse B. Preoperative and postoperative growth rates in acoustic neuromas documented with CT scanning.  Otolaryngol Head Neck Surg. 1985;  93 151-155
• 9 Ogawa K, Kanzaki J, Ogawa S, Yamamoto M, Ikeda S, Shiobara R. The growth rate of acoustic neuromas.  Acta Otolaryngol Suppl. 1991;  487 157-163
• 10 Labit-Bouvier C, Crebassa B, Bouvier C, Andrac-Meyer L, Magnan J, Charpin C. Clinicopathologic growth factors in vestibular schwannomas: a morphological and immunohistochemical study of 69 tumours.  Acta Otolaryngol. 2000;  120 950-954
• 11 Walsh R M, Bath A P, Bance M L, Keller A, Tator C H, Rutka J A. The role of conservative management of vestibular schwannomas.  Clin Otolaryngol. 2000;  25 28-39
• 12 Nutik S L, Babb M J. Determinants of tumor size and growth in vestibular schwannomas.  J Neurosurg. 2001;  94 922-926
• 13 Baser M E, Makariou E V, Parry D M. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.  J Neurosurg. 2002;  96 217-222
• 14 Beenstock M. Predicting the stability and growth of acoustic neuromas.  Otol Neurotol. 2002;  23 542-549
• 15 Irving R M, Moffat D A, Hardy D G et al.. A molecular, clinical, and immunohistochemical study of vestibular schwannoma.  Otolaryngol Head Neck Surg. 1997;  116 426-430
• 16 Diensthuber M, Brandis A, Lenarz T, Stöver T. Co-expression of transforming growth factor-beta1 and glial cell line-derived neurotrophic factor in vestibular schwannoma.  Otol Neurotol. 2004;  25 359-365
• 17 Charabi S, Thomsen J, Mantoni M et al.. Acoustic neuroma (vestibular schwannoma): growth and surgical and nonsurgical consequences of the wait-and-see policy.  Otolaryngol Head Neck Surg. 1995;  113 5-14
• 18 Fucci M J, Buchman C A, Brackmann D E, Berliner K I. Acoustic tumor growth: implications for treatment choices.  Am J Otol. 1999;  20 495-499
• 19 Mohyuddin A, Vokurka E A, Evans D G, Ramsden R T, Jackson A. Is clinical growth index a reliable predictor of tumour growth in vestibular schwannomas?.  Clin Otolaryngol. 2003;  28 85-90
• 20 Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation.  Neurosurgery. 1997;  40 1-9
• 21 Selesnick S H, Jackler R K, Pitts L W. The changing clinical presentation of acoustic tumors in the MRI era.  Laryngoscope. 1993;  103 431-436
• 22 Charabi S, Lassen N A, Thomsen J, Tos M, Rossen K, Jacobsen G K. Thallium chloride 201Tl combined with single photon emission computed tomography (SPECT) in the evaluation of vestibular schwannoma growth.  Acta Otolaryngol. 1997;  117 35-40